05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£15,240,618 |
Nicolas Loebel |
3,538,991 |
£345,052 |
Junaid Bajwa |
1,193,697 |
£116,386 |
Jean Duvall |
1,163,529 |
£113,444 |
Jean Charest |
353,356 |
£34,452 |
Simon Sinclair |
256,327 |
£24,992 |
Carolyn Cross |
118,091,377 |
£11,513,909 |
M&G Plc |
40,588,235 |
£3,957,353 |
Robert Cross |
25,858,400 |
£2,521,194 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,472,824 |
CRUX Asset Management |
9,298,090 |
£906,564 |
Chelverton Asset Management |
7,957,311 |
£775,838 |
12:53 |
30,000 @ 9.53p |
09:07 |
100,000 @ 9.50p |
09:03 |
100,000 @ 9.89p |
09:31 |
100 @ 10.00p |
09:27 |
950 @ 9.89p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research